LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia

Core Viewpoint - LB Pharmaceuticals is advancing LB-102, a potential first benzamide approved for schizophrenia in the U.S., with the initiation of the pivotal Phase 3 NOVA-2 trial aimed at evaluating its efficacy and safety [2][3][10] Company Overview - LB Pharmaceuticals is a late-stage biopharmaceutical company focused on developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases [2][10] - The company aims to leverage the therapeutic potential of LB-102, which is designed to offer a balanced clinical activity and tolerability profile [10] Product Details - LB-102 is a once-daily, orally administered investigational small molecule that acts as a selective antagonist of D2, D3, and 5HT-7 receptors [2][7] - It is a methylated derivative of amisulpride, developed to retain amisulpride's benefits while addressing its limitations [7][8] Clinical Trial Information - The NOVA-2 trial will enroll approximately 460 patients with acute exacerbation of schizophrenia across 25 sites in the U.S. [4] - Patients will be randomized to receive either 50 mg or 100 mg of LB-102 or a placebo for six weeks, with the primary endpoint being the change in PANSS total score at week 6 [4][6] - Topline results from the NOVA-2 trial are expected in the second half of 2027, with a pre-NDA meeting with the FDA anticipated if results are positive [6] Previous Trial Results - In the Phase 2 NOVA-1 trial, LB-102 demonstrated statistically significant benefits versus placebo, including rapid onset of effect at week 1 and sustained benefits [3][8] - The drug showed a potentially class-leading safety profile with low rates of extrapyramidal symptoms (EPS), minimal sedation, and few gastrointestinal side effects [3][8] Future Development Plans - The company plans to initiate an open-label extension trial involving approximately 900 patients to further explore the long-term safety and effects of LB-102 on negative symptoms and cognitive performance [5]